CD274 and non-small cell lung carcinoma: Accordingly, blockade of the interaction between PD-1 and its ligands, PD-L1 and PD-L2, is one of the most successful cancer immunotherapy modalities, especially in melanoma, renal cell cancer, and non-small cell lung cancer [28].